Xeris Biopharma Holdings Inc
For the period ended Dec 31, 2023. Filed Mar 6, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 6, 2024
XERS$15.86+4.3%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 2. Properties
Our principal office and development laboratory site are both located at 1375 West Fulton Street, Chicago, Illinois and occupy approximately 87,032 square feet of leased space. The term will expire on March 31, 2036. We believe that our offices are suitable and adequate to meet our needs.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.